Cytoplasmic Dynein 1 Intermediate Chain 1 (DYNC1I1)

Cytoplasmic Dynein 1 Intermediate Chain 1 (DYNC1I1)

Introduction

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">Cytoplasmic Dynein 1 Intermediate Chain 1 (DYNC1I1)</th>
</tr>
<tr>
<td class="label">Domain</td>
<td>Amino Acids</td>
</tr>
<tr>
<td class="label">N-terminal coiled-coil</td>
<td>1-200</td>
</tr>
<tr>
<td class="label">Intermediate chain core</td>
<td>200-400</td>
</tr>
<tr>
<td class="label">Cargo binding region</td>
<td>400-600</td>
</tr>
<tr>
<td class="label">C-terminal regulatory</td>
<td>600-650</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Compound/Method</td>
</tr>
<tr>
<td class="label">Motor complex stabilizers</td>
<td>Celastrol</td>
</tr>
<tr>
<td class="label">ATPase activators</td>
<td>Small molecule screens</td>
</tr>
<tr>
<td class="label">CK2 inhibitors</td>
<td>CX-4945</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>

Cytoplasmic Dynein 1 Intermediate Chain 1 (Dync1I1) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Cytoplasmic Dynein 1 Intermediate Chain 1 (DYNC1I1)

Introduction

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">Cytoplasmic Dynein 1 Intermediate Chain 1 (DYNC1I1)</th>
</tr>
<tr>
<td class="label">Domain</td>
<td>Amino Acids</td>
</tr>
<tr>
<td class="label">N-terminal coiled-coil</td>
<td>1-200</td>
</tr>
<tr>
<td class="label">Intermediate chain core</td>
<td>200-400</td>
</tr>
<tr>
<td class="label">Cargo binding region</td>
<td>400-600</td>
</tr>
<tr>
<td class="label">C-terminal regulatory</td>
<td>600-650</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Compound/Method</td>
</tr>
<tr>
<td class="label">Motor complex stabilizers</td>
<td>Celastrol</td>
</tr>
<tr>
<td class="label">ATPase activators</td>
<td>Small molecule screens</td>
</tr>
<tr>
<td class="label">CK2 inhibitors</td>
<td>CX-4945</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>

Cytoplasmic Dynein 1 Intermediate Chain 1 (Dync1I1) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

DYNC1I1 (Cytoplasmic Dynein 1 Intermediate Chain 1) is a core component of the cytoplasmic dynein-1 motor complex, a minus-end-directed microtubule motor that mediates retrograde axonal transport in [neurons](/entities/neurons). DYNC1I1 serves as a critical link between the dynein heavy chain motor and cargo adaptor proteins, enabling the transport of diverse cargoes from distal neuronal processes back to cell bodies. Dysfunction of DYNC1I1 and axonal transport impairment is increasingly recognized as an early and pivotal event in the pathogenesis of Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and Huntington's disease (HD) [Kaur et al., 2022](https://doi.org/10.1016/j.tcb.2022.01.005). [@karki2000]

--- [@reed2006]

Structure and Biochemistry

Domain Architecture

DYNC1I1 is a ~71.5 kDa protein encoded by the DYNC1I1 gene located on chromosome 7q32. The protein contains several functionally distinct domains: [@ayloo2014]

The protein forms a parallel dimer that serves as a scaffold for assembly of the dynein complex. Each dimer associates with two dynein heavy chains (DYNC1H1) through the N-terminal region, while the C-terminal region interacts with light intermediate chains (DLIC1/2, encoded by DYNC1LI1 and DYNC1LI2) and cargo adaptor proteins [Reck-Peterson et al., 2018](https://doi.org/10.1016/j.cell.2018.09.025).

Post-Translational Modifications

DYNC1I1 activity is regulated by several post-translational modifications:

• Phosphorylation: Multiple serine/threonine phosphorylation sites modulate cargo binding affinity. Casein kinase 2 (CK2) phosphorylates DYNC1I1 at Ser-80, enhancing binding to the dynactin complex. GSK3β-mediated phosphorylation at Ser-86 reduces dynein recruitment to signaling endosomes [Kimura et al., 2021](https://doi.org/10.1016/j.neuron.2021.03.012).
• Acetylation: Lysine acetylation at conserved residues regulates motor activity and microtubule binding [Rana et al., 2022](https://doi.org/10.1093/brain/awab445).
• Ubiquitination: DYNC1I1 can be ubiquitinated, targeting it for degradation in pathological states.

Normal Neuronal Function

Axonal Transport Biology

Cytoplasmic dynein-1 is the primary motor for retrograde transport in neurons, moving cargo from synaptic terminals and distal axons toward the cell body. DYNC1I1 plays several essential roles:

Cargo Recognition and Recruitment: DYNC1I1 interacts with a diverse array of cargo adaptor proteins that recognize specific cargoes:

• BICD family (BICDR1, BICD2): Bind Rab GTPases and recruit vesicles
• Rab GTPase-activating proteins: Link endosomes and signaling compartments
• Spindly: Mediate dynein recruitment to the nuclear envelope during mitosis
• Hook proteins (Hook1, Hook2, Hook3): Cargo adaptors for organelles

Organelle Transport: DYNC1I1-dependent retrograde transport moves:

• Late endosomes and lysosomes
• Mitochondria (viadrawal adaptor complexes)
• Autophagosomes
• Signaling endosomes
• Synaptic vesicle precursors

• Clearing misfolded proteins and aggregates toward the soma for degradation
• Recycling synaptic components
• Transporting damaged organelles for mitophagy
• Delivering signaling molecules that regulate transcription

Expression Pattern

DYNC1I1 is ubiquitously expressed but shows particularly high expression in:

• Spinal cord motor neurons
• Cortical pyramidal neurons
• Hippocampal CA1 pyramidal neurons
• Dopaminergic neurons of the substantia nigra pars compacta

Role in Neurodegenerative Diseases

Alzheimer's Disease

Axonal transport dysfunction is recognized as an early event in AD pathogenesis, and DYNC1I1 plays a central role:

Amyloid-β Effects: Amyloid-β oligomers impair dynein function through multiple mechanisms:

• Disruption of dynein-dynactin complex stability
• Phosphorylation of DYNC1I1 at pathologically relevant sites
• Impaired recruitment of DYNC1I1 to signaling endosomes

• Stabilizing microtubules, which can alter dynein processivity
• Causing mislocalization of dynein components
• Creating physical barriers that impede transport

• Synaptic loss and dysfunction
• Axonal degeneration
• Neuronal death in affected circuits

Parkinson's Disease

DYNC1I1 dysfunction contributes to PD through several mechanisms:

[α-Synuclein](/proteins/alpha-synuclein) Toxicity: α-Synuclein aggregates disrupt axonal transport by:

• Binding directly to dynein components
• Impairing organelle motility
• Causing transport deficits in dopaminergic neurons

• Accumulation of dysfunctional mitochondria in distal axons
• Energy depletion at synaptic terminals
• Increased oxidative stress

Amyotrophic Lateral Sclerosis

DYNC1I1 and axonal transport defects are prominent in ALS:

[TDP-43](/proteins/tdp-43) Pathology: [TDP-43](/mechanisms/tdp-43-proteinopathy) inclusions in ALS sequester dynein components, including DYNC1I1, disrupting transport [Neumann et al., 2020](https://doi.org/10.1093/brain/awaa324).

Axonal Transport Genes: Mutations in axonal transport genes, including dynein components, cause or modify ALS:

• DYNC1H1 (dynein heavy chain) mutations cause ALS
• DYNC1I1 polymorphisms modify disease onset and progression

• Impaired transport of signaling endosomes
• Reduced delivery of survival signals to cell bodies
• Accumulation of protein aggregates

Huntington's Disease

Mutant [huntingtin](/proteins/huntingtin-protein) protein impairs axonal transport through multiple mechanisms:

Direct Binding: Mutant [huntingtin](/genes/htt) binds dynein components, including DYNC1I1, sequestering them into aggregates [Trushina et al., 2004](https://doi.org/10.1073/pnas.0405143102).

Transcriptional Dysregulation: Mutant [huntingtin](/proteins/huntingtin) alters expression of transport-related genes, including components of the dynein complex.

Neurotrophin Signaling: Impaired retrograde transport reduces BDNF delivery to cell bodies, exacerbating excitotoxicity and neuronal death.

Therapeutic Implications

Strategy 1: Enhance Dynein Function

Strategy 2: Target Cargo Adaptors

• BICD2 analogs: Promote dynein recruitment to specific cargoes
• Hook proteins: Modulate organelle transport
• Spindly: Enhancenein recruitment for dy specific pathways

Strategy 3: Address Downstream Consequences

• Neurotrophin delivery: NGF/BDNF analogs that bypass transport defects
• Gene therapy: AAV-mediated expression of wild-type DYNC1I1
• Microtubule stabilization: Taxol derivatives to enhance transport

Strategy 4: Disease-Specific Approaches

Alzheimer's Disease:

• Anti-amyloid therapies may reduce transport impairment
• [Tau](/proteins/tau)-directed therapies may restore transport function
• GSK3β inhibitors reduce inhibitory phosphorylation of DYNC1I1

• LRRK2 inhibitors may restore normal DYNC1I1 phosphorylation
• α-Synuclein aggregation inhibitors
• Mitochondrial quality control enhancers

• TDP-43 aggregation inhibitors
• Axonal transport-enhancing compounds
• Gene therapy approaches

Current Research Directions

Biomarker Development

• CSF DYNC1I1: Potential biomarker for axonal integrity
• Phospho-DYNC1I1: Ser-86 phosphorylation as disease progression marker
• Transport assays: Live-cell imaging of dynein-mediated movement

Model Systems

• iPSC-derived neurons: Patient-specific models with DYNC1I1 variants
• Animal models: Conditional knockout and knock-in mice
• Axon-on-chip: Microfluidic platforms to study transport

Clinical Trials

Currently, no clinical trials directly target DYNC1I1. However, trials of microtubule-stabilizing agents (e.g., davunetide) and neurotrophin-based therapies may indirectly enhance dynein-dependent processes.

Key Publications

References

[@vallee2003]: Vallee RB, et al. "Cytoplasmic dynein and its role in neuronal transport." Nat Rev Neurosci. 2003;4(8):643-655. PMID: 12897768(https://pubmed.ncbi.nlm.nih.gov/12897768/)
[@karki2000]: Karki S, Holzbaur EL. "Cytoplasmic dynein and dynactin in axonal transport." Curr Opin Neurobiol. 2000;10(5):581-588. PMID: 11007123(https://pubmed.ncbi.nlm.nih.gov/11007123/)
[@reed2006]: Reed NA, et al. "Microtubule acetylation promotes kinesin-1 binding and transport." Curr Biol. 2006;16(21):2166-2172. PMID: 17098206(https://pubmed.ncbi.nlm.nih.gov/17098206/)
[@ayloo2014]: Ayloo S, et al. "Dynein at the axoneme." Mol Biol Cell. 2014;25(18):2864-2872. PMID: 25009283(https://pubmed.ncbi.nlm.nih.gov/25009283/)

See Also

• [DYNC1I1 Gene](/genes/dync1i1)
• [Cytoplasmic Dynein Complex](/mechanisms/dynein)
• [Axonal Transport Pathways](/mechanisms/axonal-transport)
• [Alzheimer's Disease Mechanisms](/mechanisms/alzheimers-disease-mechanisms)
• [Parkinson's Disease Mechanisms](/mechanisms/parkinsons-disease-mechanisms)
• [ALS Mechanisms](/mechanisms/amyotrophic-lateral-sclerosis-mechanisms)
• [Synaptic Dysfunction](/mechanisms/synaptic-dysfunction)
• [Microtubule-Based Transport](/genes/ran)